Navigation Links
ChanTest Initiates Project for the US FDA to Improve Understanding of the Interaction of Tobacco Products with Human Nicotinic Receptors
Date:8/20/2013

Cleveland (PRWEB) August 20, 2013

ChanTest, a Contract Research Organization and world leader in ion channel drug safety and discovery, announces initiation of a project funded by the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). CTP’s mission is to improve our understanding of the pharmacology of tobacco product substituent compounds and to enhance the regulation of tobacco products.

The FDA’s authority to regulate the manufacture, distribution, and marketing of tobacco products to protect public health stems from The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), which became law on June 22, 2009. The FDA's funding of this ChanTest project falls under a regulatory science initiative calling for innovation in technology to convert basic science to real-world applications.

The goals of the one-year study are to develop cell lines that express human nicotinic receptor subtypes, and to optimize high-throughput testing of exploratory compounds against nicotinic receptors in automated patch clamp and fluorometric plate-based assays. The results of the study will help the FDA gain a better understanding of the pharmacology of human nicotinic receptor subtypes and provide screening platforms for efficient characterization of tobacco-related substances.

“This project will expand our repertoire of ligand-gated ion channel test systems in the therapeutically important neuronal nicotinic receptor family. We look forward to benefiting from FDA’s extensive background in this class of targets” said ChanTest Director of Pharmacology, Glenn Kirsch, Ph.D.

Dr. Arthur “Buzz” Brown, M.D., Ph.D., ChanTest Founder and CEO, added “ChanTest has unique expertise in ion channel cell line development and cell-based functional assays, as demonstrated by our track record in ion channel safety and discovery services serving the pharmaceutical industry. We view this project as a great opportunity to interact with scientists in the area of regulatory science.”

About ChanTest – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 300 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in independent surveys since 2006. ChanTest is based in Cleveland, Ohio. For more information, e-mail info(at)chantest(dot)com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11035012.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes
5. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
8. Applied Genetics Initiates Commercial Operation
9. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
10. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
11. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016 NxGen MDx announced today ... bringing the test in house, we,ve been able to improve customer service ... for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... test volume has led to more job opportunities at the Grand Rapid ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):